Florida Cancer Specialists & Research Institute (FCS) announced the appointment of Joel Grossman, MD, and Maen Hussein, MD, to its executive board.
Joel Grossman, MD, and Maen Hussein, MD, have been appointed to the executive board at Florida Cancer Specialists & Research Institute (FCS), the organization have announced.
“Dr Grossman and Dr Hussein are outstanding physicians who always strive to do more to ensure that patients have the best possible care experience,” Lucio N. Gordan, MD, FCS president and managing physician, said. “Their willingness to serve on the executive board is further evidence of their commitment to delivering world-class cancer care in community settings.”
Maen Hussein, MD | image credit: flcancer.com
Joel Grossman, MD | image credit: flcancer.com
Grossman, a board-certified medical oncologist, has been a part of FCS since 2003. He practices oncology in Naples where he also serves as the Division Chief of Oncology and Hematology for the Naples Comprehensive Health Healthcare System. This recent appointment will mark Grossman’s fourth term on the FCS executive board. He presently serves as a member of the Electronic Medical Record (EMR) committee and previously served as the inaugural chair of the compensation committee.
Hussein—who also serves on the finance committee at FCS—has been with FCS since 2011 and has worked as the primary investigator in many clinical trials focusing on lung cancer. He has been a very active participant in cancer research and finds lots of value in clinical trial efforts. At present, he practices at FCS Brownwood and Villages Cancer Center, as well as serves as president of the Florida Society of Clinical Oncology board of directions. Furthermore, he is an active member of the board of directors and the previous chair of the FCS Foundation.
“Our executive board members have a significant impact on the direction we take and the decisions we make in this highly dynamic and rapidly changing environment," Nathan H. Walcker, MBA, FCS chief executive officer, said. "We value the expertise and insights these physicians will contribute to achieving our mission, vision, and strategic priorities.”
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen